FierceBiotechFierceBioResearcherFierceBiotechITFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Swine flu outbreak could translate into PR coup


The swine flu outbreak may be just what the pharma marketing folks need to help in their makeover of a badly tainted image.

A few years ago the vaccine industry was in disarray. But big manufacturers have jumped into the field, investing huge sums and pushing more efficient manufacturing processes. As a result, flu vaccine production has been greatly expanded and many of these global operations stand to reap a huge PR reward if they can meet expectations during this outbreak.

"It's not really about earnings accretion in 2009, it's about political goodwill with governments across the world for addressing one of the most acute public health concerns in recent history," said UBS pharmaceuticals analyst Gbola Amusa. "That political goodwill is exceptionally valuable for these pharma companies."

- read the report from the Guardian

Related Articles:
Two flu drugs better than one
Clamor for flu drugs clears store shelves
Big challenge looms over swine flu vax production
Roche, Glaxo ramping up on flu meds
Biotech companies scramble as swine flu spreads


Are you guys going to mention anything about Baxter International mixing live avian flu virus (H5N1) with regular seasonal flu virus (H3N2) vaccines in their products? It is all over other countries but not is the US....

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.